Why Are Hepion Pharma Shares Moving Higher Premarket Monday?

by Vandana Singh, Benzinga Editor

September 13, 2021 5:56 AM | 29 seconds read |

Hepion Pharmaceuticals Inc HEPA stock is moving higher during premarket ahead of additional data from its non-alcoholic steatohepatitis (NASH) trial.
Today, Hepion will share additional data from the Phase 2a AMBITION trial, evaluating CRV431, a potent inhibitor of cyclophilins involved in many disease processes.
As previously disclosed, the trial achieved all primary endpoints.
Related Content: Hepion Pharma's NASH Candidate Aces Mid-Stage Study.
Price Action: HEPA shares are up 16.9% at $1.94 during the premarket session on the last check Monday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.